image
Healthcare - Medical - Devices - NASDAQ - US
$ 0.3491
-0.824 %
$ 5.87 M
Market Cap
-0.94
P/E
1. INTRINSIC VALUE

Biomerica, Inc., a biomedical technology company, develops, patents, manufactures, and markets diagnostic and therapeutic products for the detection and/or treatment of medical conditions and diseases worldwide. The company's diagnostic test kits are used to analyze blood, urine, or fecal specimens from patients in the diagnosis of various diseases and other medical complications; or to measure the level of specific bacteria, hormones, antibodies, antigens, or other substances, which exist in the patient's body and stools or blood in extremely small concentrations. It primarily sells its products for gastrointestinal diseases, food intolerances, diabetes, and various esoteric tests at the physicians' offices and over-the-counter drugstores, and hospital/clinical laboratories.[ Read More ]

The intrinsic value of one BMRA stock under the base case scenario is HIDDEN Compared to the current market price of 0.349 USD, Biomerica, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart BMRA

image
FINANCIALS
5.42 M REVENUE
1.42%
-6.37 M OPERATING INCOME
11.85%
-5.98 M NET INCOME
16.27%
-5.36 M OPERATING CASH FLOW
2.06%
-115 K INVESTING CASH FLOW
-47.44%
-81 K FINANCING CASH FLOW
-0.86%
1.81 M REVENUE
61.92%
-1.37 M OPERATING INCOME
10.47%
-1.32 M NET INCOME
7.39%
-1.34 M OPERATING CASH FLOW
-28.74%
0 INVESTING CASH FLOW
100.00%
0 FINANCING CASH FLOW
100.00%
Balance Sheet Decomposition Biomerica, Inc.
image
Current Assets 7.73 M
Cash & Short-Term Investments 4.17 M
Receivables 947 K
Other Current Assets 2.61 M
Non-Current Assets 1.52 M
Long-Term Investments 165 K
PP&E 943 K
Other Non-Current Assets 415 K
Current Liabilities 2.2 M
Accounts Payable 288 K
Short-Term Debt 326 K
Other Current Liabilities 1.59 M
Non-Current Liabilities 459 K
Long-Term Debt 459 K
Other Non-Current Liabilities 0
EFFICIENCY
Earnings Waterfall Biomerica, Inc.
image
Revenue 5.42 M
Cost Of Revenue 4.8 M
Gross Profit 611 K
Operating Expenses 6.98 M
Operating Income -6.37 M
Other Expenses -389 K
Net Income -5.98 M
RATIOS
11.28% GROSS MARGIN
11.28%
-117.58% OPERATING MARGIN
-117.58%
-110.40% NET MARGIN
-110.40%
-90.70% ROE
-90.70%
-64.60% ROA
-64.60%
-97.28% ROIC
-97.28%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Biomerica, Inc.
image
Net Income -5.98 M
Depreciation & Amortization 374 K
Capital Expenditures -115 K
Stock-Based Compensation 837 K
Change in Working Capital -625 K
Others -510 K
Free Cash Flow -5.48 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Biomerica, Inc.
image
BMRA has no price targets from Wall Street.
4. DIVIDEND ANALYSIS
0.00% DIVIDEND YIELD
0 USD DIVIDEND PER SHARE
5. COMPETITION
6. Ownership
Insider Ownership Biomerica, Inc.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
Date Value Insider Amount Avg Price
1 year ago
May 25, 2023
Bought 310 USD
Irani Zackary S.
Chief Executive Officer
+ 200
1.55 USD
1 year ago
May 24, 2023
Bought 805 USD
Irani Zackary S.
Chief Executive Officer
+ 500
1.61 USD
1 year ago
May 12, 2023
Bought 1.99 K USD
Irani Zackary S.
Chief Executive Officer
+ 1700
1.17 USD
1 year ago
May 10, 2023
Bought 635 USD
Irani Zackary S.
Chief Executive Officer
+ 500
1.27 USD
1 year ago
May 09, 2023
Bought 417 USD
Irani Zackary S.
Chief Executive Officer
+ 300
1.39 USD
1 year ago
May 04, 2023
Bought 1.36 K USD
Irani Zackary S.
Chief Executive Officer
+ 1000
1.36 USD
1 year ago
Apr 27, 2023
Bought 3.41 K USD
Irani Zackary S.
Chief Executive Officer
+ 2600
1.31 USD
1 year ago
Apr 28, 2023
Bought 2.41 K USD
Irani Zackary S.
Chief Executive Officer
+ 1800
1.34 USD
1 year ago
Apr 26, 2023
Bought 8.82 K USD
Irani Zackary S.
Chief Executive Officer
+ 7000
1.26 USD
1 year ago
Jan 27, 2023
Bought 4.52 K USD
BARBIERI ALLEN
Executive Vice Chairman
+ 1538
2.94 USD
1 year ago
Jan 26, 2023
Bought 6.48 K USD
Coste Catherine
Director
+ 2190
2.96 USD
1 year ago
Jan 25, 2023
Bought 5.13 K USD
Irani Zackary S.
Chief Executive Officer
+ 1800
2.85 USD
1 year ago
Jan 24, 2023
Bought 5.62 K USD
Irani Zackary S.
Chief Executive Officer
+ 2000
2.81 USD
4 years ago
Oct 26, 2020
Bought 49.6 K USD
Coste Catherine
Director
+ 9100
5.45 USD
4 years ago
Apr 17, 2020
Sell 550 USD
Sirgo Mark A
Director
- 68
8.09 USD
4 years ago
Apr 17, 2020
Sell 806 USD
Sirgo Mark A
Director
- 100
8.06 USD
4 years ago
Apr 17, 2020
Sell 8.66 K USD
Sirgo Mark A
Director
- 1076
8.05 USD
4 years ago
Apr 17, 2020
Sell 10.5 K USD
Sirgo Mark A
Director
- 1302
8.07 USD
4 years ago
Apr 17, 2020
Sell 19.8 K USD
Sirgo Mark A
Director
- 2454
8.077 USD
4 years ago
Apr 21, 2020
Sell 40.5 K USD
Sirgo Mark A
Director
- 5000
8.1063 USD
6 years ago
Feb 09, 2018
Bought 1.92 K USD
Irani Zackary S.
Chief Executive Officer
+ 500
3.83 USD
6 years ago
Feb 02, 2018
Bought 3.96 K USD
Irani Zackary S.
Chief Executive Officer
+ 1000
3.96 USD
6 years ago
Jan 25, 2018
Bought 4.83 K USD
Irani Zackary S.
Chief Executive Officer
+ 1200
4.025 USD
6 years ago
Jan 25, 2018
Bought 1.4 K USD
Irani Zackary S.
Chief Executive Officer
+ 350
4.01 USD
6 years ago
Jan 25, 2018
Bought 1.98 K USD
Irani Zackary S.
Chief Executive Officer
+ 489
4.04 USD
6 years ago
Jan 23, 2018
Bought 1.92 K USD
Irani Zackary S.
Chief Executive Officer
+ 500
3.85 USD
6 years ago
Jan 25, 2018
Bought 23.8 K USD
CANO FRANCIS
Director
+ 5700
4.18 USD
6 years ago
Jan 24, 2018
Bought 836 USD
CANO FRANCIS
Director
+ 200
4.18 USD
6 years ago
Jan 25, 2018
Bought 10.4 K USD
CANO FRANCIS
Director
+ 2500
4.18 USD
6 years ago
Jan 24, 2018
Bought 14.2 K USD
CANO FRANCIS
Director
+ 3400
4.18 USD
7 years ago
Feb 27, 2017
Sell 36.8 K USD
CAPITANIO FRANCIS E
President
- 15000
2.4553 USD
7 years ago
Jan 04, 2017
Sell 9.89 K USD
MOORE JANET
Chief Financial Officer
- 4500
2.1973 USD
7 years ago
Dec 21, 2016
Sell 20.9 K USD
MOORE JANET
Chief Financial Officer
- 9600
2.1814 USD
7 years ago
Dec 22, 2016
Sell 396 USD
MOORE JANET
Chief Financial Officer
- 180
2.2 USD
7 years ago
Dec 21, 2016
Sell 20.9 K USD
MOORE JANET
Chief Financial Officer
- 9600
2.1814 USD
7 years ago
Dec 22, 2016
Sell 396 USD
MOORE JANET
Chief Financial Officer
- 180
2.2 USD
7 years ago
Dec 12, 2016
Sell 25.9 K USD
CAPITANIO FRANCIS E
President
- 9351
2.7669 USD
7 years ago
Dec 06, 2016
Sell 27.3 K USD
CAPITANIO FRANCIS E
President
- 9423
2.897 USD
7 years ago
Dec 07, 2016
Sell 2.03 K USD
CAPITANIO FRANCIS E
President
- 700
2.897 USD
7 years ago
Dec 08, 2016
Sell 1.45 K USD
CAPITANIO FRANCIS E
President
- 526
2.7627 USD
8 years ago
Nov 14, 2016
Bought 588 USD
Irani Zackary S.
Chief Executive Officer
+ 300
1.96 USD
8 years ago
Nov 10, 2016
Bought 189 USD
Irani Zackary S.
Chief Executive Officer
+ 100
1.89 USD
8 years ago
Nov 08, 2016
Bought 170 USD
Irani Zackary S.
Chief Executive Officer
+ 100
1.7 USD
8 years ago
Nov 08, 2016
Bought 700 USD
Irani Zackary S.
Chief Executive Officer
+ 400
1.75 USD
8 years ago
Nov 04, 2016
Bought 1.95 K USD
Irani Zackary S.
Chief Executive Officer
+ 1000
1.9499 USD
8 years ago
Oct 20, 2016
Sell 26.8 K USD
CAPITANIO FRANCIS E
President
- 10000
2.6841 USD
8 years ago
Oct 03, 2016
Bought 2.8 K USD
Emerson Jane
Director
+ 1000
2.8039 USD
8 years ago
Sep 07, 2016
Bought 527 USD
Irani Zackary S.
Chief Executive Officer
+ 199
2.65 USD
8 years ago
Aug 12, 2016
Bought 6.55 K USD
MOORE JANET
Chief Financial Officer
+ 2200
2.9754 USD
8 years ago
Aug 12, 2016
Bought 6.55 K USD
MOORE JANET TRUST DTD 8/21/98
+ 2200
2.9754 USD
8 years ago
Aug 12, 2016
Bought 612 USD
Irani Zackary S.
Cheif Executive Officer
+ 200
3.06 USD
8 years ago
Aug 12, 2016
Bought 716 USD
Irani Zackary S.
Cheif Executive Officer
+ 241
2.97 USD
8 years ago
Aug 12, 2016
Bought 4.5 K USD
Irani Zackary S.
Cheif Executive Officer
+ 1525
2.95 USD
8 years ago
Aug 12, 2016
Bought 3 K USD
Irani Zackary S.
Cheif Executive Officer
+ 1000
3 USD
8 years ago
Aug 12, 2016
Bought 593 USD
Irani Zackary S.
Cheif Executive Officer
+ 200
2.965 USD
8 years ago
Aug 11, 2016
Bought 1.5 K USD
Irani Zackary S.
Chief Executive Officer
+ 500
3 USD
8 years ago
Aug 11, 2016
Bought 294 USD
Irani Zackary S.
Chief Executive Officer
+ 100
2.94 USD
8 years ago
Aug 11, 2016
Bought 2.05 K USD
Irani Zackary S.
Chief Executive Officer
+ 700
2.93 USD
8 years ago
Aug 11, 2016
Bought 1.14 K USD
Irani Zackary S.
Chief Executive Officer
+ 400
2.85 USD
8 years ago
Aug 11, 2016
Bought 2.56 K USD
Irani Zackary S.
Chief Executive Officer
+ 900
2.84 USD
8 years ago
Aug 11, 2016
Bought 1.69 K USD
Irani Zackary S.
Chief Executive Officer
+ 600
2.82 USD
8 years ago
Aug 11, 2016
Bought 1.4 K USD
Irani Zackary S.
Chief Executive Officer
+ 500
2.81 USD
8 years ago
Aug 10, 2016
Bought 1.4 K USD
Irani Zackary S.
Chief Executive Officer
+ 500
2.81 USD
8 years ago
Aug 09, 2016
Bought 261 USD
Irani Zackary S.
Chief Executive Officer
+ 100
2.61 USD
8 years ago
Aug 09, 2016
Bought 1.06 K USD
Irani Zackary S.
Chief Executive Officer
+ 400
2.64 USD
8 years ago
Aug 09, 2016
Bought 11.1 K USD
CANO FRANCIS
Director
+ 4200
2.64 USD
8 years ago
Aug 09, 2016
Bought 259 USD
CANO FRANCIS
Director
+ 100
2.59 USD
8 years ago
Aug 08, 2016
Bought 347 USD
CANO FRANCIS
Director
+ 136
2.55 USD
8 years ago
Aug 08, 2016
Bought 250 USD
CANO FRANCIS
Director
+ 100
2.505 USD
8 years ago
Aug 09, 2016
Bought 2.63 K USD
BARBIERI ALLEN
Director
+ 1000
2.63 USD
8 years ago
Aug 08, 2016
Bought 5 K USD
BARBIERI ALLEN
Director
+ 2000
2.5 USD
8 years ago
Aug 05, 2016
Bought 3.92 K USD
CANO FRANCIS
Director
+ 1600
2.45 USD
8 years ago
Aug 05, 2016
Bought 1.22 K USD
CANO FRANCIS
Director
+ 500
2.43 USD
8 years ago
Aug 05, 2016
Bought 238 USD
CANO FRANCIS
Director
+ 100
2.375 USD
8 years ago
Aug 05, 2016
Bought 18.2 K USD
CANO FRANCIS
Director
+ 7600
2.4 USD
8 years ago
Aug 05, 2016
Bought 237 USD
CANO FRANCIS
Director
+ 100
2.37 USD
8 years ago
Aug 05, 2016
Bought 3.09 K USD
CANO FRANCIS
Director
+ 1300
2.38 USD
8 years ago
Aug 04, 2016
Bought 4.72 K USD
CANO FRANCIS
Director
+ 2000
2.36 USD
8 years ago
Aug 04, 2016
Bought 936 USD
CANO FRANCIS
Director
+ 400
2.34 USD
8 years ago
Aug 04, 2016
Bought 229 USD
CANO FRANCIS
Director
+ 100
2.29 USD
8 years ago
Aug 04, 2016
Bought 3.38 K USD
CANO FRANCIS
Director
+ 1500
2.25 USD
8 years ago
Aug 04, 2016
Bought 2.16 K USD
CANO FRANCIS
Director
+ 1000
2.16 USD
8 years ago
Aug 04, 2016
Bought 213 USD
CANO FRANCIS
Director
+ 100
2.13 USD
8 years ago
Aug 03, 2016
Bought 1.02 K USD
Irani Zackary S.
Chief Executive Officer
+ 500
2.05 USD
8 years ago
Aug 03, 2016
Bought 1.02 K USD
Irani Zackary S.
Chief Executive Officer
+ 500
2.05 USD
8 years ago
Aug 03, 2016
Bought 1.27 K USD
Irani Zackary S.
Chief Executive Officer
+ 609
2.09 USD
8 years ago
Aug 03, 2016
Bought 2.15 K USD
Irani Zackary S.
Chief Executive Officer
+ 1000
2.15 USD
8 years ago
Aug 03, 2016
Bought 8.2 K USD
Sirgo Mark A
Director
+ 4000
2.05 USD
8 years ago
Aug 02, 2016
Bought 4.32 K USD
Sirgo Mark A
Director
+ 2150
2.01 USD
8 years ago
Aug 02, 2016
Bought 3.7 K USD
Sirgo Mark A
Director
+ 1850
2 USD
8 years ago
Aug 01, 2016
Bought 3.58 K USD
Sirgo Mark A
Director
+ 1825
1.96 USD
8 years ago
Aug 01, 2016
Bought 346 USD
Sirgo Mark A
Director
+ 175
1.98 USD
8 years ago
Aug 01, 2016
Bought 3.8 K USD
Sirgo Mark A
Director
+ 2000
1.9 USD
8 years ago
Aug 01, 2016
Bought 3.7 K USD
Irani Zackary S.
Chief Executive Officer
+ 2000
1.85 USD
8 years ago
Aug 02, 2016
Bought 1.9 K USD
Irani Zackary S.
Chief Executive Officer
+ 900
2.11 USD
8 years ago
Aug 02, 2016
Bought 209 USD
Irani Zackary S.
Chief Executive Officer
+ 100
2.09 USD
8 years ago
Aug 01, 2016
Bought 4.32 K USD
Irani Zackary S.
Chief Executive Officer
+ 2400
1.8 USD
8 years ago
May 16, 2016
Sell 30 K USD
CAPITANIO FRANCIS E
President
- 20000
1.5 USD
8 years ago
Dec 16, 2015
Bought 2.08 K USD
Irani Zackary S.
Chief Executive Officer
+ 2000
1.04 USD
9 years ago
Nov 13, 2015
Bought 4.15 K USD
Irani Zackary S.
Chief Executive Officer
+ 5000
0.83 USD
9 years ago
Jun 08, 2015
Bought 3.24 K USD
Irani Zackary S.
Chief Executive Officer
+ 3000
1.08 USD
9 years ago
May 22, 2015
Bought 1.7 K USD
Irani Zackary S.
Chief Executive Officer
+ 2000
0.85 USD
9 years ago
Jun 08, 2015
Bought 3.24 K USD
Irani Zackary S.
Chief Executive Officer
+ 3000
1.08 USD
9 years ago
May 22, 2015
Bought 1.7 K USD
Irani Zackary S.
Chief Executive Officer
+ 2000
0.85 USD
9 years ago
May 11, 2015
Bought 6.06 K USD
Irani Zackary S.
Chief Executive Officer
+ 6000
1.01 USD
9 years ago
May 11, 2015
Bought 1.8 K USD
Irani Zackary S.
Chief Executive Officer
+ 2000
0.9 USD
9 years ago
May 11, 2015
Bought 880 USD
Irani Zackary S.
Chief Executive Officer
+ 1000
0.88 USD
9 years ago
May 11, 2015
Bought 7.65 K USD
Irani Zackary S.
Chief Executive Officer
+ 9000
0.85 USD
12 years ago
Sep 06, 2012
Bought 4.9 K USD
Irani Zackary S.
Chief Executive Officer
+ 7000
0.7 USD
12 years ago
Sep 06, 2012
Bought 4.9 K USD
Irani Zackary S.
Chief Executive Officer
+ 7000
0.7 USD
13 years ago
Feb 07, 2011
Bought 3.8 K USD
IRANI ZACHARYS
Chief Executive Officer
+ 10000
0.38 USD
16 years ago
Mar 18, 2008
Sell 3.12 K USD
MOORE JANET
Secretary
- 2500
1.25 USD
16 years ago
Mar 31, 2008
Sell 3.12 K USD
MOORE JANET
Secretary
- 2500
1.25 USD
17 years ago
Oct 23, 2007
Sell 42 K USD
CAPITANIO FRANCIS E
President - Diagnostics
- 25000
1.682 USD
17 years ago
Jul 17, 2007
Sell 1.26 K USD
CAPITANIO FRANCIS E
President - Diagnostics
- 1579
0.8 USD
17 years ago
May 25, 2007
Bought 1.4 K USD
CANO FRANCIS
Director
+ 2000
0.7 USD
17 years ago
May 25, 2007
Bought 3.75 K USD
CANO FRANCIS
Director
+ 5000
0.75 USD
17 years ago
May 25, 2007
Bought 3.7 K USD
CANO FRANCIS
Director
+ 5000
0.74 USD
17 years ago
Jul 10, 2007
Sell 4 K USD
CAPITANIO FRANCIS E
President - Diagnostics
- 5000
0.8 USD
23 years ago
Jul 10, 2001
Bought 52.1 K USD
MOORE JANET
Secretary
+ 34722
1.5 USD
21 years ago
Jun 17, 2003
Bought 4.5 K USD
MOORE JANET
Secretary
+ 18000
0.25 USD
24 years ago
Oct 01, 2000
Bought 22.4 K USD
MOORE JANET
Secretary
+ 11188
2 USD
21 years ago
Jun 17, 2003
Bought 25 K USD
IRANI ZACKARY
Chief Executive Officer
+ 100000
0.25 USD
21 years ago
Jun 17, 2003
Bought 25 K USD
IRANI ZACKARY
Chief Executive Officer
+ 100000
0.25 USD
23 years ago
Jul 10, 2001
Bought 3.12 K USD
IRANI ZACKARY
Chief Executive Officer
+ 2083
1.5 USD
21 years ago
Jun 17, 2003
Bought 4.5 K USD
MOORE JANET
Secretary
+ 18000
0.25 USD
25 years ago
Jun 10, 1999
Bought 150 K USD
MOORE JANET
Secretary
+ 50000
3 USD
23 years ago
Jul 10, 2001
Bought 52.1 K USD
MOORE JANET
Secretary
+ 34722
1.5 USD
21 years ago
May 23, 2003
Bought 5.6 K USD
MOORE JANET
Secretary
+ 20000
0.28 USD
21 years ago
Jun 17, 2003
Bought 4.5 K USD
MOORE JANET
Secretary
+ 18000
0.25 USD
24 years ago
Oct 01, 2000
Bought 22.4 K USD
MOORE JANET
Secretary
+ 11188
2 USD
25 years ago
Feb 28, 1999
Bought 6.88 K USD
MOORE JANET
Secretary
+ 8000
0.86 USD
23 years ago
Jun 12, 2001
Bought 5.22 K USD
MOORE JANET
Secretary
+ 6000
0.87 USD
7. News
Nasdaq grants Biomerica an additional 180 days to meet listing compliance requirements IRVINE, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), a leading global provider of advanced medical diagnostics, announced that it has been granted an additional 180-day compliance period from the Nasdaq Stock Market LLC ("Nasdaq") to meet the minimum $1.00 per share bid price requirement for continued listing on the Nasdaq Capital Market. This extension allows Biomerica until May 5, 2025, to regain compliance. globenewswire.com - 1 week ago
Biomerica Announces Direct-to-Consumer Availability of inFoods® IBS Test, Targeting Relief for Bloating and Gastrointestinal Pain IRVINE, Calif., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), a leading global provider of advanced medical diagnostics, is excited to announce a major enhancement to its inFoods® IBS platform. US consumers can now seamlessly order the inFoods® IBS test directly from infoodsibs.com and consequently collect a sample in the comfort of their home. As part of this ordering process, a licensed physician remotely authorizes the test, ensuring professional medical oversight, without the need for visiting a doctor's office. globenewswire.com - 2 weeks ago
Biomerica Reports First Quarter Fiscal 2025 Financial Results IRVINE, Calif., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), (the “Company”) a global provider of advanced medical diagnostic and therapeutic products today reported financial results for the first quarter of fiscal 2025 ended August 31, 2024. globenewswire.com - 1 month ago
The Saudi Food and Drug Authority (SFDA) Approves Biomerica's At Home PSA Screening Test to Detect Early Signs of Prostate Cancer - 10-Minute At-Home PSA Test for Early Detection of Prostate Cancer - First order already shipped to Saudi Arabia - Prostate Cancer is the Second Most Common Cancer in Men Globally IRVINE, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA) is pleased to announce that the Saudi Food and Drug Authority (SFDA) has approved the Company's Fortel® Prostate (PSA) Screening Test to be sold and used in the country. globenewswire.com - 2 months ago
Biomerica Reports Fiscal 2024 Year End Results IRVINE, Calif., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Biomerica, Inc. (NASDAQ: BMRA) today reported its financial results for the fiscal year ended May 31, 2024. The Company achieved a modest increase in net sales to $5.4 million, compared to $5.3 million in the prior year. This growth was primarily driven by strong demand for EZ Detect™ colorectal screening tests and Aware® breast self-exam products in the Middle East including the United Arab Emirates. globenewswire.com - 2 months ago
Biomerica Launches At-Home Sample Collection for inFoods® IBS, Significantly Expanding Access for Millions of IBS Sufferers IRVINE, Calif., July 01, 2024 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), a global provider of advanced medical products, is proud to announce a major enhancement to its inFoods® IBS system, aimed at simplifying and transforming the patient experience. globenewswire.com - 4 months ago
Biomerica Announces inFoods® IBS Pilot Launch with Prominent 1,100 Member Physician Group Commencing June 2024 IRVINE, Calif., May 13, 2024 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), (the “Company”) a global provider of advanced medical diagnostic and therapeutic products, today announced the initiation of a pilot program for its inFoods® IBS product with a large 1,100-member physician group. This pilot launch will commence in June 2024. globenewswire.com - 6 months ago
Biomerica and Leading UAE Healthcare Company Forge a Path to Enhanced Colorectal and Breast Screening with Exclusive Multi-Year Distribution Agreement IRVINE, Calif., April 29, 2024 (GLOBE NEWSWIRE) -- Biomerica Inc. (Nasdaq: BMRA), is proud to announce a multi-year exclusive distribution agreement with one of the UAE's most substantial healthcare conglomerates. This strategic alliance is set to revolutionize the accessibility and efficiency of colorectal cancer screening and breast examination technologies in the region. globenewswire.com - 6 months ago
Biomerica provides update on inFoods® IBS expansion - Expansion into new offices within current major groups, including Northeast and Ohio; Expansion into new major group in Texas. globenewswire.com - 7 months ago
Biomerica Reports Third Quarter 2024 Financial Results IRVINE, Calif., April 12, 2024 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), (the “Company”) a global provider of advanced medical diagnostic and therapeutic products today reported financial results for the third quarter of fiscal 2024 ended February 29, 2024. globenewswire.com - 7 months ago
Biomerica InFoods IBS Data to be Presented at the Upcoming Digestive Disease Week (DDW) 2024 Conference IRVINE, Calif., March 28, 2024 (GLOBE NEWSWIRE) -- Biomerica, Inc. (NASDAQ: BMRA), a global biomedical company at the forefront of innovative gastroenterology solutions, proudly announces that data from collaborators at the University of Michigan utilizing its groundbreaking inFoods IBS technologies will be presented in the IBS Clinical Session at the 2024 Digestive Disease Week (DDW) Annual Meeting in Washington DC. DDW is renowned as the world's premier scientific and clinical meeting for digestive disease health care professionals. globenewswire.com - 7 months ago
Diagnostics Industry Leader Gary Huff Appointed to Biomerica Strategic Advisory Board Mr. Huff was the Former CEO of LabCorp Diagnostics and joins with significant executive experience and a proven track record in medical diagnostics and healthcare Mr. Huff was the Former CEO of LabCorp Diagnostics and joins with significant executive experience and a proven track record in medical diagnostics and healthcare globenewswire.com - 8 months ago
8. Profile Summary

Biomerica, Inc. BMRA

image
COUNTRY US
INDUSTRY Medical - Devices
MARKET CAP $ 5.87 M
Dividend Yield 0.00%
Description Biomerica, Inc., a biomedical technology company, develops, patents, manufactures, and markets diagnostic and therapeutic products for the detection and/or treatment of medical conditions and diseases worldwide. The company's diagnostic test kits are used to analyze blood, urine, or fecal specimens from patients in the diagnosis of various diseases and other medical complications; or to measure the level of specific bacteria, hormones, antibodies, antigens, or other substances, which exist in the patient's body and stools or blood in extremely small concentrations. It primarily sells its products for gastrointestinal diseases, food intolerances, diabetes, and various esoteric tests at the physicians' offices and over-the-counter drugstores, and hospital/clinical laboratories. The company is also developing InFoods, an irritable bowel syndrome therapy technology and diagnostic-guided therapy; Helicobacter pylori products, as well as develops, tests, validates, and sells diagnostic products for COVID-19 infection. Biomerica, Inc. was incorporated in 1971 and is headquartered in Irvine, California.
Contact 17571 Von Karman Avenue, Irvine, CA, 92614 https://www.biomerica.com
IPO Date Sept. 7, 1984
Employees 64
Officers Mr. Zackary S. Irani Chief Executive Officer & Director Mr. Gary Lu CPA Principal Accounting Officer & Chief Financial Officer Mr. Robert W. Carlson Chief Commercial Officer Mr. Allen C. Barbieri Executive Vice-Chairman of the Board & Corporate Secretary Ms. Lucy Liu Ph.D. Director of Manufacturing & Technical Operations